AbbVie on Track for Record High Close -- Data Talk
Dow Jones · 57m ago
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q2 2024
AbbVie reported earnings per share of $2.65 for the second quarter of 2024. The company reported revenue of $14.46 billion. This was 3.08% better than the analyst estimate for revenue. Abbvie also reported results for the first quarter of 2025.
Investorplace · 1h ago
New Drug Sales Lift AbbVie Shares
The Wall Street Journal · 1h ago
AbbVie Stock News: Why ABBV Is the Top Trending Ticker Today
AbbVie started its earnings report for Q2 with adjusted EPS of $2.65. The company reported revenue of $14.462 billion. Warner Bros. Discovery (WBD) stock and Chipotle (CMG) are among the stocks moving on Thursday. 2U (NASDAQ:TWOU) stock is up 5.2% as of Thursday morning.
Investorplace · 2h ago
ABBV Earnings: AbbVie Surpasses Q2 Expectations with Strong Immunology Sales
TipRanks · 2h ago
AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
Benzinga · 2h ago
AbbVie Exec Announces Discontinuation Of Further Development Of Experimental Alzheimer's Drug ABBV-916 As Standalone Antibody
Benzinga · 3h ago
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
NASDAQ · 3h ago
Cerevel ticks higher as AbbVie says it expects deal to close soon
Seeking Alpha · 3h ago
4 stocks to watch on Thursday: LUV, LINE and more
Seeking Alpha · 3h ago
AbbVie Stock Is Rising on Strong Earnings. CEO Cites 'Significant Momentum.'
Barron‘s · 4h ago
AbbVie raises outlook as new immunology drugs offset Humira impact
Seeking Alpha · 4h ago
Abbvie Inc: Current report
Press release · 5h ago
AbbVie 2Q Revenue Gets Boost From Skyrizi, Rinvoq Sales
Dow Jones · 5h ago
AbbVie in charts: Skyrizi, Rinvoq sales jump, while Humira revenue falls ~30% Y/Y in Q2
Seeking Alpha · 5h ago
Earnings summary: AbbVie reports mixed Q2 results; raises FY24 EPS outlook
Seeking Alpha · 5h ago
AbbVie Boosts FY24 Outlook - Update
NASDAQ · 5h ago
Is AbbVie the Best Dividend Stock for You?
AbbVie's Humira is out of patent exclusivity in the U.S. The drugmaker has a rich lineup of products, including 11 blockbuster products. Even without Humira, Abbvie's revenue grew in the first quarter. The company has a 52-year streak of consecutive dividend increases. Abb vie is a great stock for investors.
The Motley Fool · 5h ago
AbbVie’s quarterly results top estimates as newer drugs cushion Humira’s slide
MarketWatch · 5h ago
AbbVie Non-GAAP EPS of $2.65 misses by $0.01, revenue of $14.46B beats by $430M
Seeking Alpha · 5h ago
Webull provides a variety of real-time ABBV stock news. You can receive the latest news about Abbvie Inc through multiple platforms. This information may help you make smarter investment decisions.
About ABBV
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology, which include Humira, Skyrizi and Rinvoq; oncology, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. It offers NX-13, a first-in-class, oral NLRX1 agonist, for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). It also offers CEL383, a first-in-class anti-TREM1 antibody, for the treatment of inflammatory bowel disease.